Congenital disorders of glycosylation (CDG): Quo vadis?
Year: 2017
Type: review
Abstract: The survey summarizes in its first part the current status of knowledge on the Congenital Disorders of Glycosylation (CDG) with regard to their phenotypic spectrum, diagnostic and therapeutic strategies, and pathophysiology. It documents the clinical and basic research activities, and efforts to involve patients and their families. In the second part, it tries to look into the future of CDG. More specific biomarkers are needed for fast CDG diagnosis and treatment monitoring. Whole genome sequencing will play an increasingly important role in the molecular diagnosis of unsolved CDG. Epigenetic defects are expected to join the rapidly expanding genetic and allelic heterogeneity of the CDG family. Novel treatments are urgently needed particularly for PMM2-CDG, the most prevalent CDG. Patient services such as apps should be developed e.g. to document the natural history and monitor treatment. Networking (EURO-CDG, the European Reference Networks (MetabERN)) is an efficient tool to disseminate knowledge and boost collaboration at all levels. The final goal is of course to improve the quality of life of the patients and their families.
Institutions: KU Leuven, Hôpital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, Institut des Maladies Génétiques Imagine, Université Paris Descartes, Université de Lille, Unité de Glycobiologie Structurale et Fonctionnelle, Berlin-Brandenburger Centrum für Regenerative Therapien, Stiftung Charité, Charité – Universitätsmedizin Berlin, Radboud University Medical Center, Consejo Superior de Investigaciones Científicas, Centre for Biomedical Network Research on Rare Diseases, Universidad Autónoma de Madrid, Laboratoire de Biochimie, Hôpital Bichat-Claude-Bernard, Heidelberg University, de Duve Institute, UCLouvain
Language: English
Subfield: Biochemistry
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,330
Awards: G252738700, G434337789
OpenAlex ID: W2765845687
